The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A systemic review and meta-analysis to evaluate the efficacy and postprogression survival of second-line chemotherapy for gemcitabine-refractory pancreatic cancer.
 
Akiyoshi Kasuga
No Relationships to Disclose
 
Yasuo Hamamoto
No Relationships to Disclose
 
Yu Aoki
No Relationships to Disclose
 
Kenta Kawasaki
No Relationships to Disclose
 
Takeshi Suzuki
No Relationships to Disclose
 
Kenro Hirata
No Relationships to Disclose
 
Yasutaka Sukawa
No Relationships to Disclose
 
Hiromasa Takaishi
No Relationships to Disclose
 
Takanori Kanai
Consulting or Advisory Role - Ajinomoto (Inst); Takeda (Inst)
Speakers' Bureau - Ajinomoto; Astellas Pharma; AstraZeneca; Miyarisan Pharmaceutical; Pfizer; Takeda
Research Funding - Biofermin Pharmaceutical (Inst); Mitsubishi Tanabe Pharma (Inst); Takeda (Inst)